SURVEILLANCE OF HUMANPAPILLOMAVIRUS IN FEMALE BONE MARRO

女性骨髓中人乳头瘤病毒的监测

• 批准号: 6132996
• 负责人: DONNA E SALZMAN
• 金额: $ 5.59万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-04-01 至 2002-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6132996
• 关键词: DNA replication; artificial immunosuppression; bone marrow transplantation; cervical /vaginal smear; cervix neoplasms; clinical research; comorbidity; condyloma acuminatum; cytotoxic T lymphocyte; epidemiology; female; gene expression; graft versus host disease; helper T lymphocyte; host organism interaction; human papillomavirus; human subject; immunoglobulin G; leukocyte count; longitudinal human study; pathologic process; polymerase chain reaction; suppressor T lymphocyte; vagina neoplasms; virus genetics

Current data suggest that the clinical expression and progression of humanpapillomavirus (HPV)-associated disease occurs more rapidly in immunosuppressed patients, and it is feasible to study genital HPV infections at the clinical, pathologic, and molecular level in this population. Bone Marrow Transplant (BMT) recipients represent a growing number of immunosuppressed patients who are known to have a pronounced susceptibility to viral infections as a consequence of impaired T-cell mediated cytotoxicity. Given that 40-70 percent of sexually active people are infected with one or more genital HPV types, it is plausible that female BMT recipients may have reactivation of latent infections. To date, female BMT recipients have not been evaluated for genital HPV nor do guidelines for cervical cancer screening exist in this immunosuppressed population. The purpose of this study is to describe the molecular epidemiology of cervicovaginal HPV infection in women who are undergoing BMT and to determine the effect of specific HPV types on the clinical and pathologic course of genital infection. This study will also determine the correlation of dynamic HPV gene expression, DNA replication, and host responses to infection and their relation to changes in clinical, pathologic, and histopathologic features of genital HPV and the degree of BMT-related immunosuppression and subsequent immune reconstitution. All female BMT patients 18 years or older will be eligible. Patients will be followed prospectively and receive evaluations prior to BMT, and at important follow-up visits. HPV viral pathogenic events will be assessed through the use of both routine and innovative techniques to detect not only the presence of HPV, but also measure early markers of viral expression that may correlate with disease progression leading to cervical neoplasia.

当前的数据表明，在免疫抑制的患者中，人毛细血管瘤病毒（HPV）相关疾病的临床表达和进展更快，并且可以在该人群中研究临床，病理学和分子水平的生殖器HPV感染。 骨髓移植（BMT）受体代表了越来越多的免疫抑制患者，由于T细胞介导的细胞毒性受损，人们已知对病毒感染具有明显的病毒感染敏感性。 鉴于40-70％的性活跃的人感染了一种或多种生殖器HPV类型，因此女性BMT接受者可能会重新激活潜在感染是合理的。 迄今为止，尚未评估女性BMT接受者的生殖器HPV，也没有在这种免疫抑制人群中进行宫颈癌筛查指南。 这项研究的目的是描述正在接受BMT的女性中宫颈阴道HPV感染的分子流行病学，并确定特定的HPV类型对生殖器感染的临床和病理病程的影响。 这项研究还将确定动态HPV基因表达，DNA复制和对感染的宿主反应的相关性及其与生殖器HPV的临床，病理和组织病理学特征的变化以及它们与BMT相关的免疫抑制程度的关系以及随后的免疫机构的关系。 所有18岁以上的女性BMT患者均符合条件。 前瞻性遵循患者，并在BMT之前接受评估，并进行重要的随访。 HPV病毒致病事件将通过使用常规技术和创新技术来评估，不仅检测HPV的存在，还可以测量可能与疾病进展相关的病毒表达的早期标记，从而导致宫颈肿瘤。